Reading this on a mobile device? Try our optimized mobile version here:

January 7, 2013News for medical technology professionals

  Top Story 
  • Delphinus pursues FDA OK for breast cancer device
    Delphinus Medical Technologies has submitted an application with the FDA for its SoftVue system, a 3D imaging device that could provide doctors with a safer and more precise alternative to mammograms in diagnosing breast cancer. CEO William Greenway said he hopes the company will get an FDA OK to begin marketing the device during the first half of 2013. Detroit Free Press (1/6) LinkedInFacebookTwitterEmail this Story
  Business & Market Trends 
  • Lifecodes to become part of Immucor
    Hologic has entered a deal to sell its subsidiary Lifecodes to Immucor for $85 million. Lifecodes is a provider of molecular and antibody-based assays for businesses specializing in transplant diagnostics, specialty coagulation and transfusion medicine. The deal is expected to be finalized in the second fiscal quarter. (free registration) (1/4) LinkedInFacebookTwitterEmail this Story
  • Ceterix Orthopaedics obtains $19.5M in funding round
    A round of financing from five investors has pulled in $19.5 million for Ceterix Orthopaedics, which hopes to obtain an additional $1.10 million. The Menlo Park, Calif.-based startup is the maker of a suturing device that helps doctors stitch challenging anatomical areas while avoiding surrounding tissue, cartilage or nerves. (1/5) LinkedInFacebookTwitterEmail this Story
  International Developments 
  • New medical device vigilance guidelines take effect in Egypt
    The Egyptian Drug Authority has finalized guidelines governing its medical device vigilance program, which details responsibilities for the agency's Medical Device Safety Department, device users and manufacturers. The guidance took effect on Jan. 1 and includes changes to a draft version released in 2011, including a new section on in vitro diagnostics. Clinica (subscription required) (1/4) LinkedInFacebookTwitterEmail this Story
  Science & Health 
  • Partnership aims to improve prenatal diagnostics
    Baylor College of Medicine will work with Chinese firm Berry Genomics to enhance the way prenatal genetic testing is performed. The partnership will allow BCM to combine its gene-chip microarray tools, which are used to analyze chromosome structure, with Berry Genomics' systems for assessing fetal DNA derived from maternal plasma. GenomeWeb Daily News (free registration) (1/4) LinkedInFacebookTwitterEmail this Story
  Emerging Technologies 
  • Soft Tissue's device to repair rotator cuff wins FDA nod
    Soft Tissue Regeneration has been cleared by the FDA to market a biodegradable scaffold for patients in need of rotator cuff repair and soft tissue augmentation. The STR Graft, set to be commercially available in 2014, is intended to reduce pain, minimize surgical failure and expedite patient recovery time. Healio (1/4) LinkedInFacebookTwitterEmail this Story

Interested in learning more about advertising with SmartBrief? Click here for detailed industry information and media kits. 

  Hot Topics 

Top five news stories selected by AdvaMed SmartBrief readers in the past week.

  • Results based on number of times each story was clicked by readers.
  Government & Regulatory 
  • Minn. group aims to reverse changes to 510(k) process
    The Minnesota Medical Device Alliance has filed a petition asking the FDA to discontinue certain definitions and administrative measures that the group says unlawfully alter the 510(k) clearance process. The petition cites practices adopted by the FDA since 2009, including wrongly applying "assurance case" and risk mitigation principles to 510(k) criteria. (1/4) LinkedInFacebookTwitterEmail this Story
AdvaMed News 
  • Investigational Device Exemption (IDE) Submissions Workshop
    Wednesday, Feb. 27
    Sheraton Crystal City, Arlington, Va.
    MTLI offers this one-day interactive workshop to lead attendees through the regulatory and practical guidelines governing when an IDE is required, how to compile an effective IDE application, the rules governing clinical studies and human subject protection, Institutional Review Boards, types of pre-IDE meetings and communications, early/expanded access, foreign studies and export, and reimbursement for investigational devices. Visit MTLI online for more information. LinkedInFacebookTwitterEmail this Story
  • Join the AdvaMed-MTLI LinkedIn group!
    Build close relationships with member companies, both small and large, and receive an intimate understanding of the key issues affecting innovation, access and the bottom line. Interact in discussions that leverage the leadership and expertise of the medical technology industry. This social group is full of key stakeholders, influencers and industry thought leaders as well as regulatory and policy experts from the FDA and CMS. Aside from practical learning opportunities, this LinkedIn group provides the premier opportunity to network with key players from virtually every aspect of the industry. Link to the AdvaMed MTLI LinkedIn group page. LinkedInFacebookTwitterEmail this Story
Learn more about AdvaMed ->About AdvaMed | Join | Courses | Events | Newsroom

Position TitleCompany NameLocation
Program Director, Regulatory AffairsJohnson & JohnsonFremont, CA
Quality Systems ManagerRoche DiagnosticsIndianapolis, IN
IP Litigation Counsel - 001980Edwards LifesciencesIrvine, CA
Click here to view more job listings.

If money be not thy servant, it will be thy master. The covetous man cannot so properly be said to possess wealth, as that may be said to possess him."
--Francis Bacon,
British author and statesman

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Account Director:  Meryl Harold (202) 407-7828
Job Board:  Jackie Basso (202) 407-7871
A powerful website for SmartBrief readers including:
 Recent AdvaMed SmartBrief Issues:   Lead Editor:  Lisa Gough
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2013 SmartBrief, Inc.® Legal Information